The future of off-the-shelf CAR-T

Allogeneic approach could bring cell therapy to more patients more quickly, biopharma executives say.

September 8, 2023 Check out STAT+

Sponsored By

STAT STAT+ | Cancer care appears brighter as off-the-shelf CAR-T advances Allogeneic approach could bring cell therapy to more patients more quickly, biopharma executives say. By Elizabeth Cooney Robert Winn: Without 'high-touch' strategies, cancer's breakthroughs will increase disparities Outreach and practical problem-solving, the cancer center director says, are essential to make advances reach all communities. By Angus Chen Opinion: What a viral study criticizing cancer screening gets very, very wrong The complex math behind screening befuddled the researchers' attempts to assess whether screening helped people live longer. By Peter B. Bach

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser